Drug Profile
S 234462
Alternative Names: S-234462Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Shionogi
- Class Obesity therapies
- Mechanism of Action Neuropeptide Y5 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Obesity
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for phase-I development in Obesity in USA (PO)
- 11 Aug 2011 Phase I development is ongoing in USA
- 17 Feb 2010 Phase-I clinical trials in Obesity in USA (PO)